

Reinventing Drug Discovery, from Retrospective to Perspectives

Confirmed Speakers

Vision for the Future of Drug Discovery

Vision, Agility, Mindset: Catalyzing the Transformation of Drug Discovery for Patients at Servier (KL19)

Dr Claude BERTRAND
(INSTITUT DE RECHERCHES SERVIER, GIF-SUR-YVETTE, France)

Vision for the Future of Drug Discovery: Solving Big Problems and the Opportunities of Scientific and Technological Advances (KL18)

Dr Karin BRINER
(GENENTECH, South San Francisco, United States)

25 Years of Thinking Small (KL14)

Dr Harren JHOTI
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Enabling New Paradigms in Drug Discovery Through Biophysical Characterization - virtual lecture (KL13)

Dr Frank LAUKIEN (BRUKER, Billerica, United States)

Dr Falko BUSSE (BRUKER SWITZERLAND, Fällanden, Switzerland)

Adding Years of Life and Quality of Life: How the Healthcare Industry Can Bring Value to the World (KL15)

Dr Paul STOFFELS
(GALAPAGOS, Beerse, Belgium)

Present and Future Tools for Drug Discovery

Open Chemical Probes and Data-Driven Hit-Finding for Target Characterization and Validation (KL01)

Prof. Cheryl ARROWSMITH
(STRUCTURAL GENOMICS CONSORTIUM, Toronto, Canada)

Biophysics: Opportunities and Challenges in the Evolving Landscape of Early Drug Discovery (KL12)

Dr Maria M. FLOCCO
(ASTRAZENECA, Cambridge, United Kingdom)

Where AI Meets the Real World (KL11)

Dr Dave HALLETT
(EXSCIENCIA LTD, Oxford, United Kingdom)

Title of talk to be confirmed (KL02)

Prof. Holger STARK
(MAX PLANCK INSTITUTE FOR MULTIDISCIPLINARY SCIENCES, Göttingen, Germany)

New Modalities as New Frontiers of Drug Discovery

Biophysics for Protein Degraders: It's all in the Ternary Complex (KL03)

Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Chance Favors the Perplexed Mind: The Critical Role of Biochemistry and Biophysics in the Development of Small Molecule Inhibitors of Chromatin- and RNA-Modifying Enzymes as Precision Cancer Therapeutics (KL04)

Dr Robert COPELAND
(ACCENT THERAPEUTICS, INC., Lexington, United States)

Induced Proximity: Exploring New Therapeutic Modalities (KL05)

Reinventing Drug Discovery, from Retrospective to Perspectives

Confirmed Speakers

Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, CT, United States)

Unmet Therapeutic Needs : Current Challenges

History, Achievements, Promises, and Issues of Gene Therapy (KL10)

Dr Serge BRAUN
(AFM TÉLÉTHON, Evry, France)

Building a Pipeline of High-Impact Products to Prevent, Diagnose and Treat Bacterial Infections (KL17)

Dr Erin DUFFY
(CARB-X, Boston, United States)

Drug Discovery for Neglected Patients: Past Experience, Present Strategy and Future Directions (KL16)

Dr Charlie MOWBRAY
(DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI), Geneva, Switzerland)

Challenges and Opportunities in Cancer Therapy: a Perspective Across Modalities (KL09)

Dr Tobias SCHMELZLE
(NOVARTIS, Basel, Switzerland)

Financial Perspectives on the Future of the Industry

Title of talk to be announced (KL06)

Dr Matthias BUCHER
(CEPTON STRATEGIES, Paris, France)

Title of talk to be announced (KL08)

Dr Vanessa MALIER
(IVIBIOPUS, Paris, France)

Financing Early Stage Life Sciences Innovation in Europe: a New Model of Venture Building (KL07)

Dr Magali RICHARD
(HOME BIOSCIENCES, Paris, France)

Round table Contributors

Dr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

Dr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

Dr Sylwia HUBER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Dr Sandra JACOB
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Reinventing Drug Discovery, from Retrospective to Perspectives

Confirmed Speakers

Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)